Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank100
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$67.99M
↑ 185% vs avg
Percentile
P100
Near historical high
Streak
1 yr
Consecutive growthExpanding
Average
$-79.88M
Historical baseline
PeriodValueYoY Change
2025$67.99M+267.1%
2024$-40.69M-74.0%
2023$-23.38M+68.1%
2022$-73.27M+71.0%
2021$-253.02M-128.6%
2020$-110.70M+58.1%
2019$-264.10M-166.5%
2018$-99.10M-71.5%
2017$-57.78M-204.6%
2016$55.24M-